<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01670604</url>
  </required_header>
  <id_info>
    <org_study_id>KAH012</org_study_id>
    <nct_id>NCT01670604</nct_id>
  </id_info>
  <brief_title>Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures</brief_title>
  <official_title>The Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures: Effect on Acid-Base Status and Renal Functions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect of infusion of two types of modern hydroxyethyl starch on the
      renal function and acid-base in patients undergoing urologic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative volume replacement therapy</measure>
    <time_frame>From randomization, for the duration of surgery and up to transfer from the operating room to the ICU or recovery room, an expected average of 6 hours</time_frame>
    <description>volume of the study drug in milliliters that will be needed for hemodynamic stabilization until the end of surgery (ie, the cumulative volume of the study drug in milliliters administered up to this time point).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acid base and Renal function</measure>
    <time_frame>24 hours after randomization</time_frame>
    <description>differences in the plasma creatinine concentrations and acid-base homeostasis among the study groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Urologic Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>VOL group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TET group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will receive 6% HES 130/0.42 in a balanced electrolyte containing Na+140 mmol/L, Cl- 118 mmol/L, K +4 mmol/L, Ca++ 2.5 mmol/L, Mg++ 1 mmol/L, acetate- 24 mmol/L and malate-- 5 mmol/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)</intervention_name>
    <arm_group_label>VOL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetraspan, B. Braun, Melsungen, Germany</intervention_name>
    <arm_group_label>TET group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age group above 18 years,

          -  ASA І and ІІ,

          -  Patients who will be scheduled to undergo radical prostatectomy or cystectomy with
             bladder replacement

        Exclusion Criteria:

          -  A known allergy to HES,

          -  Renal insufﬁciency (serum creatinine of &gt;2.5 mg/dL),

          -  Signiﬁcant hepatic disease (liver function tests more than three times the upper limit
             of normal),

          -  Coagulation disorders (INR &gt; 1.5).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amr Hussein, MSc</last_name>
    <phone>01069338998</phone>
    <phone_ext>+2</phone_ext>
    <email>amrhussein1981@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Mukhtar, MD</last_name>
    <phone>01114208444</phone>
    <phone_ext>+2</phone_ext>
    <email>Ahmed.Mukhtar@kasralainy.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasralainy Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11559</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amr Hussein, MSc</last_name>
      <phone>01069338998</phone>
      <phone_ext>+2</phone_ext>
      <email>amrhussein1981@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Abeer Ahmed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nazmy Seif, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Helmy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Mukhtar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amr Hussein, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Kluft C, Jenks RL, Astrup T. Production of plasminogen actovatpr activity in factor XII-deficient plasma. Thromb Res. 1977 May;10(5):759-64.</citation>
    <PMID>18813</PMID>
  </reference>
  <reference>
    <citation>Takayanagi I, Maruyama M, Takagi K. Beta-adrenoceptors in the guinea pig treated with egg-albumin. Jpn J Pharmacol. 1977 Apr;27(2):314-6.</citation>
    <PMID>18633</PMID>
  </reference>
  <reference>
    <citation>Mitchell AR, Erickson BW, Ryabtsev MN, Hodges RS, Merrifield RB. Tert-butoxycarbonylaminoacyl-4-(oxymethyl)-phenylacetamidomethyl-resin, a more acid-resistant support for solid-phase peptide synthesis. J Am Chem Soc. 1976 Nov 10;98(23):7357-62.</citation>
    <PMID>10319</PMID>
  </reference>
  <reference>
    <citation>Birke ER. [On the action of antihypotensive agents in sympathicotonic orthostatic hypotension in geriartric patients: comparison between placebo and etilefrin (author's transl)]. Med Klin. 1977 Oct 14;72(41):1696-702. German.</citation>
    <PMID>21345</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2012</study_first_submitted>
  <study_first_submitted_qc>August 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2012</study_first_posted>
  <last_update_submitted>August 20, 2012</last_update_submitted>
  <last_update_submitted_qc>August 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Mukhtar</investigator_full_name>
    <investigator_title>Assistant professor of anesthesia Cairo University</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

